Editorial Commentary:Improving the Treatment ofClostridium difficile–Associated Disease: Where Should We Start?
Open Access
- 1 September 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (5), 553-555
- https://doi.org/10.1086/506357
Abstract
There are few common infectious diseases occurring in developed countries for which the treatments used in 2006 are essentially the same as those recommended onKeywords
This publication has 28 references indexed in Scilit:
- Molecular Analysis of Clostridium difficile PCR Ribotype 027 Isolates from Eastern and Western CanadaJournal of Clinical Microbiology, 2006
- Clostridium difficileRibotype 027, Toxinotype III, the NetherlandsEmerging Infectious Diseases, 2006
- Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal DisordersClinical Infectious Diseases, 2006
- Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, IsraelDiagnostic Microbiology and Infectious Disease, 2006
- Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with MetronidazoleClinical Infectious Diseases, 2005
- In Vitro Activity of Ramoplanin against Clostridium difficile , Including Strains with Reduced Susceptibility to Vancomycin or with Resistance to MetronidazoleAntimicrobial Agents and Chemotherapy, 2005
- Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severityCMAJ : Canadian Medical Association Journal, 2004
- In vitro Activity of Rifaximin, Metronidazole and Vancomycin against Clostridium difficile and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing SpeciesChemotherapy, 2000
- Comparison of Vancomycin, Teicoplanin, Metronidazole, and Fusidic Acid for the Treatment of Clostridium difficile--Associated DiarrheaClinical Infectious Diseases, 1996
- Clinical Pharmacokinetics of RifampicinClinical Pharmacokinetics, 1978